ConductScience.org, home

Paper3000790

Variable bioavailability following repeated oral doses of etoposide.

Harvey VJ and 5 others. Eur J Cancer Clin Oncol, 1985. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. Variable bioavailability following repeated oral doses of etoposide. Papers, record 3000790. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3000790

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Variable bioavailability following repeated oral doses of etoposide.
PubMed
Journal
Eur J Cancer Clin Oncol
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
2.65
iCite
Revised in PubMed
2019-09-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Harvey VJV J
2Slevin MLM L
3Joel SPS P
4Smythe MMM M
5Johnston AA
6Wrigley PFP F

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EtoposideMajor topic
PodophyllotoxinMajor topic
Adult
Biological Availability
Carcinoma, Small Cell
Drug Administration Schedule
Humans
Kinetics
Lung Neoplasms
Mesothelioma
Time Factors

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
37594527Novel Meta-iodobenzylguanidine and Etoposide Complex: Physicochemical Characterization and Mathematical Modeling of Anticancer Activity.AAPS PharmSciTech2023https://conductscience.org/library/papers/37594527PubMed
15956976Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.Br J Cancer2005https://conductscience.org/library/papers/15956976PubMed
15139794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
10958591The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.Invest New Drugs2000https://conductscience.org/library/papers/10958591PubMed
9400945Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.Br J Cancer1997https://conductscience.org/library/papers/9400945PubMed
9184183Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.Br J Cancer1997https://conductscience.org/library/papers/9184183PubMed
8797893Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer.Jpn J Cancer Res1996https://conductscience.org/library/papers/8797893PubMed
8609070Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.Jpn J Cancer Res1996https://conductscience.org/library/papers/8609070PubMed
8286205Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.Br J Cancer1994https://conductscience.org/library/papers/8286205PubMed
8258198A limited sampling model for the pharmacokinetics of etoposide given orally.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8258198PubMed
7497587Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497587PubMed
7497581Pharmacological attempts to improve the bioavailability of oral etoposide.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497581PubMed
7497580Stability of the i.v. and oral formulations of etoposide in solution.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497580PubMed
3621455Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3621455PubMed
3555940Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet1987https://conductscience.org/library/papers/3555940PubMed
3315283Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3315283PubMed
3311530Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.Clin Pharmacokinet1987https://conductscience.org/library/papers/3311530PubMed
3297462The clinical pharmacology of etoposide and teniposide.Clin Pharmacokinet1987https://conductscience.org/library/papers/3297462PubMed
3004772The effect of dose on the bioavailability of oral etoposide.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3004772PubMed
2758563The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2758563PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3000790

GET https://conductscience.org/api/papers/v1/3000790/cited_by?page=2